Inovio Pharmaceuticals Inc. Stock Advances 12.1%, Outperforms Competitors

Dow JonesFeb 12 16:33 ET

Inovio Respiratory DNA Drug Candidate Shows Promise in Early Trial

Seeking AlphaFeb 12 08:31 ET

Express News | INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

BenzingaFeb 12 08:04 ET

Express News | Inovio Pharmaceuticals Inc - Phase 1/2 Study Results of Ino-3107 Published in Nature Communications

ReutersFeb 12 08:01 ET

Express News | Immune Response Data for Ino-3107 to Be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

ReutersFeb 10 08:05 ET

Immune Response Data for INO-3107 to Be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

PR NewswireFeb 10 08:05 ET